PLANO, Texas, June 6, 2017 /PRNewswire/ -- Argon Medical Devices, Inc. (Argon), a leading global manufacturer and marketer of specialty medical devices used in interventional procedures, announced today that it has formalized a Medical Advisory Board comprised of distinguished physicians from institutions across the United States who specialize in interventional medicine. The Medical Advisory Board will continue to provide scientific and clinical expertise to guide the organization in planning and implementing product development initiatives and marketing programs with the goal of improving the lives of patients and their caregivers.
Argon welcomes seven members to the Medical Advisory Board: James F. Benenati, M.D., FSIR, Miami Cardiac & Vascular Institute, Miami, FL; Jim Caridi, M.D., FSIR, Tulane University Medical Center; Matthew S. Johnson, M.D., FSIR, IU Health (Indiana University Health), Indianapolis, IN; John A. Kaufman, M.D., M.S., Oregon Health & Science University, Portland, OR; John Moriarty, M.D., RPVI, UCLA Medical Center, Santa Monica, CA; Robert K. Ryu, M.D., FSIR, University of Colorado Hospital, Aurora, CO; and David W. Trost, M.D., Weill Medical College of Cornell University, New York, NY.
“We are very pleased to introduce the founding members of Argon’s Medical Advisory Board. Their knowledge and expertise in interventional procedures provide a unique and unparalleled perspective, which helps us drive innovation to meet customer needs,” said George Leondis, President and CEO of Argon.
About the Advisory Board Members:
James F. Benenati, M.D., FSIR, is a practicing interventional radiologist, clinical researcher and medical director of the Miami Cardiac & Vascular Institute’s Peripheral Vascular Laboratory in Miami. He is the Fellowship Program Director for the Cardiovascular and Interventional Radiology Fellowship Program, which is recognized internationally as an elite training program. He is a Clinical Professor of Radiology at Florida International University’sHerbert Wertheim College of Medicine, Miami, and a Clinical Associate Professor of Radiology at the University of South Florida Morsani College of Medicine, Tampa.
Jim Caridi, M.D., FSIR, is Professor of Vascular and Interventional Radiology at Tulane University Medical Center. In 2013, Dr. Caridi moved to Tulane University Medical Center as an attending in Vascular and Interventional Radiology. Since that time, he has become Chairman of the Department of Radiology.
Matthew S. Johnson, M.D., FSIR, is the Director of Interventional Oncology at IU Health and Professor of Radiology and Surgery at IU School of Medicine in Indianapolis. He also has appointments as the Gary J. Becker Professor of Radiology Research, Director of Clinical Research in the Department of Radiology and Professor in the Department of Surgery at IU School of Medicine. His areas of interest include treatment of primary and secondary liver tumors; radioembolization and other locoregional therapies; treatment assessment and validation; imaging response (CT, MR, PET) versus survival benefit; histologic basis of treatment response; and therapeutic synergies.
John A. Kaufman, M.D., M.S., is the Director of the Dotter Interventional Institute and the Frederick S. Keller Professor of Interventional Radiology at the Oregon Health & Science University (OHSU) in Portland. He also has an appointment as Professor of Diagnostic Radiology, Surgery and Medicine at OHSU. His research focuses on vena cava filters and aortic stentgrafts. Dr. Kaufman has authored or co-authored more than 200 publications, including five textbooks.
John Moriarty, M.D., RPVI, is a specialist in vascular and interventional radiology at the University of California, Santa Monica (UCLA). He is a member of both the Departments of Radiology and of Medicine (cardiology); the Director of the IVC Filter Clinic, the UCLA PE Response Team (UPERT) and the program for Interventional Innovation; and co-Director of Vascular Ultrasound Service.
Robert K. Ryu, M.D., FSIR, is Chief of Vascular and Interventional Radiology at University of Colorado Hospital (UCH) in Aurora as well as a Professor of Interventional Radiology. Dr. Ryu’s clinical interests include venous thromboembolic disease and interventional oncology, specifically liver-directed therapies for the treatment of hepatic malignancies.
David W. Trost, M.D., is the Associate Professor of Clinical Radiology and Director of Interventional Radiology at the Weill Medical College of Cornell University, New York. He also serves as the Associate Attending Radiologist at the New York Presbyterian Hospital. Dr. Trost currently serves as reviewer for Radiology, Transplantation and the Journal of Vascular and Interventional Radiology as well as examiner for the American Board of Radiology.
For full physician biographies and to learn more about Argon, visit http://argonmedical.com/.
Follow Argon on Twitter and LinkedIn.
About Argon Medical Devices, Inc.
Argon Medical Devices, Inc., based in Plano, TX, is a privately held, global manufacturer and marketer of single-use specialty medical devices for interventional procedures. Through a network of direct sales representatives and premier distributors, Argon supplies physician customers with breakthrough technologies to improve clinical efficiency and outcomes. The Argon product portfolio is highlighted by the OptionELITE Retrievable IVC Filter, CLEANER XT and CLEANER 15 Rotational Thrombectomy Systems, BioPince Full Core Biopsy Instrument, TLAB Transjugular Liver Biopsy Instrument, Atrieve Vascular Snare, SKATER Drainage Systems and T-Lok Bone Marrow Biopsy Needles.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/argon-medical-devices-inc-formalizes-medical-advisory-board-300465825.html
SOURCE Argon Medical Devices, Inc.
